Report cover image

Global Major Histocompatibility Complex Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 195 Pages
SKU # APRC20360850

Description

Summary

According to APO Research, the global Major Histocompatibility Complex market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Major Histocompatibility Complex is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Major Histocompatibility Complex is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Major Histocompatibility Complex market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Major Histocompatibility Complex is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Major Histocompatibility Complex market include Santa Cruz Biotechnology, ProImmune, Novus Biologicals, Miltenyi Biotec, Creative BioMart and Abbexa, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Major Histocompatibility Complex, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Major Histocompatibility Complex, also provides the value of main regions and countries. Of the upcoming market potential for Major Histocompatibility Complex, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Major Histocompatibility Complex revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Major Histocompatibility Complex market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Major Histocompatibility Complex company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Major Histocompatibility Complex Segment by Company

Santa Cruz Biotechnology
ProImmune
Novus Biologicals
Miltenyi Biotec
Creative BioMart
Abbexa

Major Histocompatibility Complex Segment by Type

MHC Class II
MHC Class III
MHC Class I

Major Histocompatibility Complex Segment by Application

Medical Care
Research
Other

Major Histocompatibility Complex Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Major Histocompatibility Complex status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Major Histocompatibility Complex key companies, revenue, market share, and recent developments.
3. To split the Major Histocompatibility Complex breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Major Histocompatibility Complex market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Major Histocompatibility Complex significant trends, drivers, influence factors in global and regions.
6. To analyze Major Histocompatibility Complex competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Major Histocompatibility Complex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Major Histocompatibility Complex and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Major Histocompatibility Complex.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Major Histocompatibility Complex industry.
Chapter 3: Detailed analysis of Major Histocompatibility Complex company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Major Histocompatibility Complex in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Major Histocompatibility Complex in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Major Histocompatibility Complex Market Size, 2020 VS 2024 VS 2031
1.3 Global Major Histocompatibility Complex Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Major Histocompatibility Complex Market Dynamics
2.1 Major Histocompatibility Complex Industry Trends
2.2 Major Histocompatibility Complex Industry Drivers
2.3 Major Histocompatibility Complex Industry Opportunities and Challenges
2.4 Major Histocompatibility Complex Industry Restraints
3 Major Histocompatibility Complex Market by Company
3.1 Global Major Histocompatibility Complex Company Revenue Ranking in 2024
3.2 Global Major Histocompatibility Complex Revenue by Company (2020-2025)
3.3 Global Major Histocompatibility Complex Company Ranking (2023-2025)
3.4 Global Major Histocompatibility Complex Company Manufacturing Base and Headquarters
3.5 Global Major Histocompatibility Complex Company Product Type and Application
3.6 Global Major Histocompatibility Complex Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Major Histocompatibility Complex Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Major Histocompatibility Complex Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Major Histocompatibility Complex Market by Type
4.1 Major Histocompatibility Complex Type Introduction
4.1.1 MHC Class II
4.1.2 MHC Class III
4.1.3 MHC Class I
4.2 Global Major Histocompatibility Complex Sales Value by Type
4.2.1 Global Major Histocompatibility Complex Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Major Histocompatibility Complex Sales Value by Type (2020-2031)
4.2.3 Global Major Histocompatibility Complex Sales Value Share by Type (2020-2031)
5 Major Histocompatibility Complex Market by Application
5.1 Major Histocompatibility Complex Application Introduction
5.1.1 Medical Care
5.1.2 Research
5.1.3 Other
5.2 Global Major Histocompatibility Complex Sales Value by Application
5.2.1 Global Major Histocompatibility Complex Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Major Histocompatibility Complex Sales Value by Application (2020-2031)
5.2.3 Global Major Histocompatibility Complex Sales Value Share by Application (2020-2031)
6 Major Histocompatibility Complex Regional Value Analysis
6.1 Global Major Histocompatibility Complex Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Major Histocompatibility Complex Sales Value by Region (2020-2031)
6.2.1 Global Major Histocompatibility Complex Sales Value by Region: 2020-2025
6.2.2 Global Major Histocompatibility Complex Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Major Histocompatibility Complex Sales Value (2020-2031)
6.3.2 North America Major Histocompatibility Complex Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Major Histocompatibility Complex Sales Value (2020-2031)
6.4.2 Europe Major Histocompatibility Complex Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Major Histocompatibility Complex Sales Value (2020-2031)
6.5.2 Asia-Pacific Major Histocompatibility Complex Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Major Histocompatibility Complex Sales Value (2020-2031)
6.6.2 South America Major Histocompatibility Complex Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Major Histocompatibility Complex Sales Value (2020-2031)
6.7.2 Middle East & Africa Major Histocompatibility Complex Sales Value Share by Country, 2024 VS 2031
7 Major Histocompatibility Complex Country-level Value Analysis
7.1 Global Major Histocompatibility Complex Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Major Histocompatibility Complex Sales Value by Country (2020-2031)
7.2.1 Global Major Histocompatibility Complex Sales Value by Country (2020-2025)
7.2.2 Global Major Histocompatibility Complex Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.3.2 USA Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.4.2 Canada Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.6.2 Germany Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.7.2 France Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.7.3 France Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.9.2 Italy Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.10.2 Spain Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.11.2 Russia Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.14.2 China Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.14.3 China Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.15.2 Japan Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.17.2 India Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.17.3 India Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.18.2 Australia Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.22.2 Chile Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.24.2 Peru Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.26.2 Israel Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.27.2 UAE Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.29.2 Iran Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Major Histocompatibility Complex Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Major Histocompatibility Complex Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Major Histocompatibility Complex Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Santa Cruz Biotechnology
8.1.1 Santa Cruz Biotechnology Comapny Information
8.1.2 Santa Cruz Biotechnology Business Overview
8.1.3 Santa Cruz Biotechnology Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.1.4 Santa Cruz Biotechnology Major Histocompatibility Complex Product Portfolio
8.1.5 Santa Cruz Biotechnology Recent Developments
8.2 ProImmune
8.2.1 ProImmune Comapny Information
8.2.2 ProImmune Business Overview
8.2.3 ProImmune Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.2.4 ProImmune Major Histocompatibility Complex Product Portfolio
8.2.5 ProImmune Recent Developments
8.3 Novus Biologicals
8.3.1 Novus Biologicals Comapny Information
8.3.2 Novus Biologicals Business Overview
8.3.3 Novus Biologicals Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.3.4 Novus Biologicals Major Histocompatibility Complex Product Portfolio
8.3.5 Novus Biologicals Recent Developments
8.4 Miltenyi Biotec
8.4.1 Miltenyi Biotec Comapny Information
8.4.2 Miltenyi Biotec Business Overview
8.4.3 Miltenyi Biotec Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.4.4 Miltenyi Biotec Major Histocompatibility Complex Product Portfolio
8.4.5 Miltenyi Biotec Recent Developments
8.5 Creative BioMart
8.5.1 Creative BioMart Comapny Information
8.5.2 Creative BioMart Business Overview
8.5.3 Creative BioMart Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.5.4 Creative BioMart Major Histocompatibility Complex Product Portfolio
8.5.5 Creative BioMart Recent Developments
8.6 Abbexa
8.6.1 Abbexa Comapny Information
8.6.2 Abbexa Business Overview
8.6.3 Abbexa Major Histocompatibility Complex Revenue and Gross Margin (2020-2025)
8.6.4 Abbexa Major Histocompatibility Complex Product Portfolio
8.6.5 Abbexa Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.